Personalized medicine

PathAI Announces Two New Executives to Expand Regulatory Expertise and Precision Oncology Commercial Strategy

Retrieved on: 
Thursday, February 16, 2023
Science, Biotechnology, Research, Oncology, Health, Artificial Intelligence, Technology, Clinical Trials, Foundation Medicine, Medicine, Personalized medicine, Regulatory affairs, NGS, FDA Center for Devices and Radiological Health, Food, European Medicines Agency, Pathology, Sutro Biopharma, Knowledge, FDA, Growth, MPH, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, AstraZeneca, Medical device

These new leaders will build on the company’s position at the forefront of AI-driven pathology and will advance its growth in the precision diagnostics market with their regulatory and commercial expertise.

Key Points: 
  • These new leaders will build on the company’s position at the forefront of AI-driven pathology and will advance its growth in the precision diagnostics market with their regulatory and commercial expertise.
  • With deep experience in regulatory and strategic issues across the precision medicine field, Dr. Madison brings strong cross-functional expertise to PathAI, with a focus on the development of oncology products, both diagnostic and therapeutic.
  • Madison brings exceptional talent to PathAI, combining knowledge in precision oncology and companion diagnostics, an understanding of the regulatory requirements for innovative diagnostics, and therapeutic development experience,” said Nick Brown, Chief Commercial Officer for Biopharma and Digital Diagnostics at PathAI.
  • Madison will help propel PathAI forward in the oncology space by refining our companion diagnostic strategy and broader offerings to oncology developers.”

Global Induced Pluripotent Stem Cell (iPSC) Industry Report 2023: Profiles Leading Market Competitors, Including FUJIFILM CDI, ReproCELL, Evotec, Ncardia, and Axol Bioscience - ResearchAndMarkets.com

Retrieved on: 
Monday, February 13, 2023
Health, Stem Cells, Macular degeneration, Regenerative medicine, Cellular Dynamics International, B cell, Toxicology, Game Industry Report Magazine, Human, Thermo Fisher Scientific, Drug development, Therapy, IPSC, Medicine, Cell, 3D bioprinting, Safety, University of Wisconsin–Madison, Patient, CRISPR, Clinical trial, CLI, University, CDI, Research, MSC, Tissue engineering, Merck, Graft-versus-host disease, Kyoto University, Personalized medicine, Disease, Partnership, OA, COVID-19, Drug discovery, Microsoft Exchange Server, Osteoarthritis, Pharmaceutical industry, Veterinary medicine, Mobile phone, Fine chemical

The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts, 2023" report has been added to ResearchAndMarkets.com's offering.
  • Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine.
  • Personalized Medicine:The use of techniques such as CRISPR enables precise, directed the creation of knock-outs and knock-ins (including single base changes) in many cell types.
  • Headquartered in Cambridge, UK, it specializes in human cell culture, providing iPSC-derived cells and iPSC-specific cell culture products.

Majority of Cambridge Research Papers Now Open Access

Retrieved on: 
Monday, February 6, 2023
Education, Communications, Research, Publishing, Science, University, Climate, ChemRxiv, Personalized medicine, Assessment, Cambridge University Press & Assessment, Publication, Cambridge University Press, Medicine, Plastic, American Political Science Association, Water, University of Cambridge, APSA, Student, Humanities, Map, Partnership, OA, Social, Book, Pharmaceutical industry, Management

Having passed the 50 percent threshold for last year – approximately 10,000 papers being fully open – Cambridge University Press is aiming for the vast majority of its research papers to be published fully open access by 2025.

Key Points: 
  • Having passed the 50 percent threshold for last year – approximately 10,000 papers being fully open – Cambridge University Press is aiming for the vast majority of its research papers to be published fully open access by 2025.
  • Cambridge hitting this open access milestone is especially remarkable, as about 60 percent of its research publications are in the humanities and social sciences - fields where research funding constraints have historically held back open research adoption, relative to science, technology and medicine.
  • Over 400 Cambridge journals offer open access options to publishers; 66 with fully open access and 340 hybrid.
  • “That’s why we will not stop at half of our journal papers being open access: we are working to make the vast majority of such research fully open by 2025.

Weill Cornell Medicine and NanoString Collaborate to Create Comprehensive Spatial Atlas of Human Anatomy

Retrieved on: 
Thursday, February 2, 2023
Biotechnology, Health, Genetics, Science, Research, SAHA, Pathology, DSP, Personalized medicine, Protein, RNA, SVP, SMI, Data analysis, Organelle, Medical laboratory, Physiology, CSO, DRS, Transcriptome, Weill Cornell Medicine, John J. Carty Award for the Advancement of Science, NanoString Technologies, Human body, Medical imaging, Microscope, Biophysics

The goal is to create a comprehensive open source, spatial reference standard that can be accessed by researchers around the globe to advance our knowledge of spatial biology.

Key Points: 
  • The goal is to create a comprehensive open source, spatial reference standard that can be accessed by researchers around the globe to advance our knowledge of spatial biology.
  • “The goal is for SAHA to be a foundational database that can serve as a benchmark reference for spatial precision medicine.
  • Comparing spatial datasets of various organs from multiple ethnicities can capture the variability in samples that researchers do not currently understand,” stated Chris Mason, Professor of Physiology and Biophysics, Weill Cornell Medicine.
  • SAHA is a collaborative effort with Weill Cornell Medicine’s Department of Pathology and Laboratory Medicine, Englander Institute for Precision Medicine, and the WorldQuant Initiative for Quantitative Prediction.

The Worldwide Consumer Genomics Industry is Expected to Reach $9 Billion by 2027: Increase in Access to DTC Services due to Reducing the Cost of Genotyping Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 23, 2023
Other Health, Men, Family, Consumer, Medical Devices, Genetics, Science, Women, Biotechnology, Medical Supplies, Other Science, Health, Co-production (public services), Investment, Emotion, Ansoff matrix, COVID-19, Market development, Geography, Porter's five forces analysis, Impact, System, SWOT, Risk, Diagnosis, USD, Consumables, Personalized medicine, Growth, Observation, Ancestor, Retail, Risk management, Medical device, Application

These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service.

Key Points: 
  • These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service.
  • The report presents a detailed Ansoff matrix analysis for the Global Consumer Genomics Market.
  • Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.
  • The report offers a comprehensive evaluation of the Global Consumer Genomics Market.

IQHQ Appoints Janice Sears and Anshul Mangal as Independent Members to its Board of Directors

Retrieved on: 
Monday, January 23, 2023
Health, Commercial Building & Real Estate, Construction & Property, General Health, REIT, Biotechnology, Electricity, University of Illinois Chicago School of Law, Purdue University, Chemical Bank, Retirement, Personalized medicine, United Kingdom, Refugee, Commercial, Jones, Marketing, NYSE, Patient, Real estate, Jones Day, University of Illinois Chicago School of Public Health, University, Computer, Bank of America, Chicago-Kent College of Law, Bank, Citigroup, Sears, Invitation Homes, Management, Science, Economics

IQHQ, Inc., a premier life sciences real estate development company, today announced key additions to its Board of Directors – naming Janice Sears and Anshul Mangal as independent directors.

Key Points: 
  • IQHQ, Inc., a premier life sciences real estate development company, today announced key additions to its Board of Directors – naming Janice Sears and Anshul Mangal as independent directors.
  • “We are pleased to add Janice and Anshul to our esteemed Board of Directors,” said Steve Rosetta, CEO of IQHQ.
  • “Janice brings an unparalleled track record of financial, investor, and commercial real estate expertise, which will play a critical role in our future growth plans.
  • “I am excited to join the IQHQ Board of Directors and use my expertise to further the development of IQHQ’s portfolio,” said Mangal.

Boston Children's Hospital names Wendy Chung, MD, PhD, Chief of the Department of Pediatrics

Retrieved on: 
Tuesday, February 14, 2023
HMS, Medical director, Cornell University, Mentorship, Columbia University Irving Medical Center, Simons Foundation Autism Research Initiative, SPARK, Personalized medicine, Organization, Weill Cornell Medicine, Boston, NIH, Division, Columbia University, Education, Teaching, Hospital, Rockefeller University, Harvard Medical School, Morgan Stanley Children's Hospital, Research, SFARI, Genetics, Herbert Irving Comprehensive Cancer Center, Associate, Spectrum, Economics, Herbert, Doctor of Philosophy, Nursing, Pediatrics, Biochemistry, Boston Children's Hospital, Medicine, MD

BOSTON, Feb. 14, 2023 /PRNewswire/ -- Boston Children's Hospital has named Wendy Chung, MD, PhD, the hospital's next Chief of the Department of Pediatrics.

Key Points: 
  • BOSTON, Feb. 14, 2023 /PRNewswire/ -- Boston Children's Hospital has named Wendy Chung, MD, PhD, the hospital's next Chief of the Department of Pediatrics.
  • Dr. Chung will be responsible for leadership, strategy, oversight, and vision for the Department of Pediatrics, ensuring alignment with the goals, strategic priorities and mission of Boston Children's, the Physician's Organization, and Harvard Medical School.
  • In addition to her role as Chief of the Department of Pediatrics, Dr. Chung will serve as the Mary Ellen Avery Professor at Harvard Medical School (HMS), and President of the Children's Hospital Pediatric Associates.
  • "Dr. Chung is a tremendous addition to our Boston Children's team," says Kevin B. Churchwell, MD, President and CEO Boston Children's Hospital.

Sunitha Mathew to Become Westat's New Clinical Research Practice Director

Retrieved on: 
Thursday, February 9, 2023
National Heart, Lung, and Blood Institute, Personalized medicine, NIH, Lung, Administration, Research, Epidemiology, Data science, CDC, Clinical, Public health, Strategy, Electronic health record, Health information management, Centers for Disease Control and Prevention, COVID-19, MS, NHLBI, Lead, Nursing, Management, Westat

ROCKVILLE, Md., Feb. 9, 2023 /PRNewswire/ -- Effective February 2, 2023, Sunitha Mathew, MS, Vice President, has joined Westat's leadership team as its new Clinical Research Practice Director, reporting to Patricia Shifflett, MS, Vice President, Health Sector Lead.

Key Points: 
  • ROCKVILLE, Md., Feb. 9, 2023 /PRNewswire/ -- Effective February 2, 2023, Sunitha Mathew, MS , Vice President, has joined Westat's leadership team as its new Clinical Research Practice Director, reporting to Patricia Shifflett, MS, Vice President, Health Sector Lead.
  • Ms. Mathew joined Westat in 2002 and has extensive experience directing key business and health research initiatives pivotal to organizational growth.
  • This includes 20+ years of experience overseeing complex clinical, epidemiological, and translational research programs.
  • Prior to taking on this new role, Ms. Mathew was a Vice President in Public Health.

Exact Sciences Launches OncoExTra™ Cancer Therapy Selection Test in the U.S.

Retrieved on: 
Tuesday, February 7, 2023
DNA, City, Physician, ASCO, Personalized medicine, Exome, American Society of Clinical Oncology, Biology, CGP, NGS, IHC, Oncology, Medicare, Patient, Clinical trial, RNA, Exact sciences, Neoplasm, Journal of the National Comprehensive Cancer Network, Health care, Transcriptome, Gene, Disease, City of Hope National Medical Center, MPH, Society, Cancer, MD, Pharmaceutical industry, Medical imaging, Doctor of Philosophy

MADISON, Wis., Feb. 7, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of the OncoExTra™ therapy selection test in the United States. OncoExTra is a next-generation sequencing (NGS), comprehensive DNA and RNA based genomic test providing doctors and their patients a complete molecular picture of the patient's cancer. The test provides reliable and actionable results personalized to each patient.

Key Points: 
  • MADISON, Wis., Feb. 7, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of the OncoExTra™ therapy selection test in the United States.
  • OncoExTra is a next-generation sequencing (NGS), comprehensive DNA and RNA based genomic test providing doctors and their patients a complete molecular picture of the patient's cancer.
  • "With this test, I have a much better picture of my patient's cancer, allowing me to prescribe the most effective treatment for their specific solid tumor."
  • "Exact Sciences continues to build its leadership in cancer diagnostics by offering innovative tests addressing clinical needs at every step of patient cancer care," said Kevin Conroy, chairman and CEO of Exact Sciences.

A.I. Sustainability Framework Opportunity Zones Located

Retrieved on: 
Thursday, January 26, 2023
History, COVID-19, Personalized medicine, Death, COVID, Learning, Health, Swiss Re, Ethics, Imagination, Communication, Knowledge management, World Health Organization, American Farm Bureau Federation, Research, Science, Pharmaceutical industry

Using state-of-the-art technology in ways that integrate societal and individual health with patient-centered approaches is its essential core.

Key Points: 
  • Using state-of-the-art technology in ways that integrate societal and individual health with patient-centered approaches is its essential core.
  • This translational model transcends economic and geographic boundaries and disparities by harnessing available technologies and best practices.
  • The platform is a cross-disciplinary hub that spans business, industry, science, big data tech, media, research, philanthropy, venture funds, and ethical care delivery.
  • Framework supports progress while leveraging and scaling humanity's technological potential to do good," shared Kristin Raffaelle.